Legal & General Group Plc Takes Position in Twist Bioscience Corporation $TWST

Legal & General Group Plc bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the second quarter, HoldingsChannel.com reports. The fund bought 121,980 shares of the company’s stock, valued at approximately $12,549,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quarry LP bought a new stake in Twist Bioscience in the third quarter valued at $28,000. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the 1st quarter valued at $31,000. Strs Ohio bought a new stake in shares of Twist Bioscience in the 1st quarter worth about $33,000. Strategic Advocates LLC grew its holdings in shares of Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after purchasing an additional 906 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its position in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares in the last quarter.

Twist Bioscience Stock Down 1.7%

Shares of TWST opened at $139.00 on Tuesday. The business’s fifty day moving average price is $108.03 and its two-hundred day moving average price is $74.64. The firm has a market capitalization of $8.72 billion, a price-to-earnings ratio of -62.61 and a beta of 2.14. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $155.44. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.33 EPS. On average, analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 41,570 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the transaction, the chief executive officer directly owned 770,729 shares in the company, valued at approximately $117,135,393.42. This represents a 5.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares in the company, valued at $10,402,335.08. This trade represents a 2.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 193,099 shares of company stock valued at $24,026,581. 3.08% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have commented on TWST. Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a research report on Thursday, July 16th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price on the stock. in a report on Monday, July 6th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Finally, Piper Sandler raised their price target on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $98.30.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.